C

CRVS

CRVS

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
100%Bullish
Buy/Sell Ratio100% buys
BearishBullish
CRVS Live QuoteReal-time
$9.67
$0.98(-9.20%)1M
Day Range$9.55 – $10.03
Open$9.84
Previous Close$10.01
Volume927.5K
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$850.28M
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-0.72
Price to Book4.1
Dividend Yield0.65%
Beta (Volatility)1.52
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $9.67 (16%)
Low: $6.39High: $26.95
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$31.50-79.0% upside

Insider Buys

1

$50K

Insider Sales

0

$0

Total Volume

$50K

1 transactions

Net Activity

+$50K

Net buying

Proprietary Ratings
Calculated from Form 4 transactions
65CONFIDENCE

Sentiment Rating

Moderate Accumulation

CEO Conviction Index

No Recent Signal

Key Drivers

  • •Strong buying bias: purchases represent 100% of total transaction value.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
A
1

Arcara Jeffrey

Chief Business Officer

1 buys0 sells

$50K total

Trading History
CRVS insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Nov 11, 2026

1 weeks ago

Arcara Jeffrey

Chief Business Officer

C-Level
Buy4.5K$11.22$50K
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
CRVS Buy Conviction100%
Industry Rank#493 of 569
Volume Contribution0.0%
Total Industry Activity$16.52B

CRVS has an insider buy conviction of 100%, compared to the Unknown sector buy average of 6%. CRVS ranks #493 in insider activity out of 569 tracked companies in its industry.

Insider Trading Summary & Commentary
Automated executive transaction analysis for CRVS

Over the last 90 days, corporate insiders at CRVS (CRVS) engaged in a total of 1 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 0 were sales. The total volume of insider trading reached $50K.

The net insider activity for CRVS shows a net buying bias of $50K. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Purchase by Arcara Jeffrey (Chief Business Officer), who traded 4.5K shares valued at $50K on Nov 11, 2026.

Live Market News & Developments
Aggregated real-time headlines for CRVS (CRVS)
6 updates

CRVS - Corvus Pharmaceuticals Inc Stock Price and Quote

Finviz177d ago

Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans

Yahoo Finance300d ago

A London conference webcast will remain available for 90 days after Corvus presents.

Stock Titan11d ago

Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know (CRVS)

Seeking Alpha303d ago

Corvus Pharmaceuticals: CRVS Stock Price Quote & News

Robinhood1160d ago

Insider Buys Additional US$250k In Corvus Pharmaceuticals Stock

Simply Wall St156d ago

FAQs About CRVS Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for CRVS.

Based on SEC Form 4 disclosures, the Insider Confidence Score for CRVS is currently 65/100, which reflects a moderate accumulation bias. This calculation accounts for a total of 1 purchases and 0 sales by company executives over the last 90 days.

The CEO Conviction Index for CRVS is rated as "No Recent Signal". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.